Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major

Abstract

To determine whether deferoxamine prevents the complications of transfusional iron overload in thalassemia major, we evaluated 59 patients (30 were female and 29 male; age range, 7 to 31 years) periodically for 4 to 10 years or until death.